← All trials
NCT02194699
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2014
- Primary completion
- May 10, 2017
- Completion date
- Sep 28, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 856
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Institute for Lung Health, United KingdomOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.